

Melissa A Geller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9379627/publications.pdf>

Version: 2024-02-01

55
papers

3,320
citations

218381

26
h-index

189595

50
g-index

56
all docs

56
docs citations

56
times ranked

6181
citing authors

#	ARTICLE	IF	CITATIONS
1	Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation. <i>Translational Oncology</i> , 2022, 16, 101318.	1.7	12
2	Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2138-2147.	0.8	40
3	Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. <i>Science Translational Medicine</i> , 2022, 14, eabg8402.	5.8	28
4	Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 193-198.	0.6	4
5	Differences in Family Planning and Fertility Among Female and Male Gynecologic Oncologists. <i>Women S Health Reports</i> , 2021, 2, 78-84.	0.4	3
6	Sonosensitizerâ€Functionalized Graphene Nanoribbons for Adhesion Blocking and Sonodynamic Ablation of Ovarian Cancer Spheroids. <i>Advanced Healthcare Materials</i> , 2021, 10, 2001368.	3.9	16
7	Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager. <i>Cancer Immunology Research</i> , 2020, 8, 1139-1149.	1.6	39
8	NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. <i>Cancers</i> , 2020, 12, 2659.	1.7	54
9	Immobilization rapidly selects for chemoresistant ovarian cancer cells with enhanced ability to enter dormancy. <i>Biotechnology and Bioengineering</i> , 2020, 117, 3066-3080.	1.7	5
10	<p>Ultrasound-guided subcostal transversus abdominis plane block with liposomal bupivacaine compared to bupivacaine infiltration for patients undergoing robotic-assisted and laparoscopic hysterectomy: a prospective randomized study</p>. <i>Journal of Pain Research</i> , 2019, Volume 12, 2087-2094.	0.8	21
11	Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. <i>Nature Communications</i> , 2019, 10, 567.	5.8	193
12	Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells. <i>Gynecologic Oncology</i> , 2019, 153, 149-157.	0.6	79
13	Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer. <i>JAMA Oncology</i> , 2019, 5, 1222.	3.4	19
14	Sexual quality of life after the treatment of gynecologic cancer: what women want. <i>Supportive Care in Cancer</i> , 2019, 27, 4649-4654.	1.0	21
15	A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial. <i>Gynecologic Oncology</i> , 2019, 153, 100-107.	0.6	17
16	Effect of an Electronic Health Record Decision Support Alert to Decrease Excess Cervical Cancer Screening. <i>Journal of Lower Genital Tract Disease</i> , 2019, 23, 253-258.	0.9	5
17	Excess Cost of Cervical Cancer Screening Beyond Recommended Screening Ages or After Hysterectomy in a Single Institution. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 184-188.	0.9	9
18	Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. <i>JCI Insight</i> , 2018, 3, .	2.3	165

#	ARTICLE	IF	CITATIONS
19	Effects of web-based instruction and patient preferences on patient-reported outcomes and learning for women with advanced ovarian cancer: A randomized controlled trial. <i>Journal of Psychosocial Oncology</i> , 2018, 36, 503-519.	0.6	16
20	A qualitative study of barriers to genetic counseling and potential for mobile technology education among women with ovarian cancer. <i>Hereditary Cancer in Clinical Practice</i> , 2018, 16, 13.	0.6	18
21	Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018, 151, 18-23.	0.6	18
22	Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells. <i>Gynecologic Oncology</i> , 2017, 144, 598-606.	0.6	82
23	Gene expression markers of Tumor Infiltrating Leukocytes. , 2017, 5, 18.		572
24	The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: A randomized, sham-controlled clinical trial. <i>Gynecologic Oncology</i> , 2017, 144, 159-166.	0.6	30
25	Tunneling nanotube formation is stimulated by hypoxia in ovarian cancer cells. <i>Oncotarget</i> , 2016, 7, 43150-43161.	0.8	108
26	A model for patient-direct screening and referral for familial cancer risk. <i>Familial Cancer</i> , 2016, 15, 707-716.	0.9	14
27	Long term follow-up of a phase II trial of multimodal therapy given in a "sandwich" method for stage III, IV, and recurrent endometrial cancer. <i>Gynecologic Oncology Research and Practice</i> , 2016, 3, 6.	3.6	6
28	Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer. <i>Stem Cells</i> , 2016, 34, 93-101.	1.4	181
29	Designing an Educational Website to Improve Quality of Supportive Oncology Care for Women with Ovarian Cancer: An Expert Usability Review and Analysis. <i>International Journal of Human-Computer Interaction</i> , 2016, 32, 297-307.	3.3	11
30	A phase I feasibility study of multi-modality imaging assessing rapid expansion of marrow fat and decreased bone mineral density in cancer patients. <i>Bone</i> , 2015, 73, 90-97.	1.4	27
31	Propensity-Weighted Comparison of Long-Term Risk of Urinary Adverse Events in Elderly Women Treated For Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 586-593.	0.4	11
32	A multi-institutional study of outcomes in stage "III uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2015, 139, 275-282.	0.6	25
33	Ultrasound guided subcostal transversus abdominis plane (TAP) infiltration with liposomal bupivacaine for patients undergoing robotic assisted hysterectomy: A prospective randomized controlled study. <i>Gynecologic Oncology</i> , 2015, 138, 609-613.	0.6	91
34	Improving Referral for Genetic Risk Assessment in Ovarian Cancer Using an Electronic Medical Record System. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1003-1009.	1.2	24
35	Cervical cytology and multiple type HPV infection: A study of 8182 women ages 31"65. <i>Gynecologic Oncology</i> , 2014, 133, 405-408.	0.6	64
36	Bariatric surgery-induced weight loss changes immune markers in the endometrium of morbidly obese women. <i>Surgery for Obesity and Related Diseases</i> , 2014, 10, 921-926.	1.0	24

#	ARTICLE	IF	CITATIONS
37	Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug. <i>Gynecologic Oncology</i> , 2014, 135, 318-324.	0.6	26
38	A feasibility study to identify proteins in the residual Pap test fluid of women with normal cytology by mass spectrometry-based proteomics. <i>Clinical Proteomics</i> , 2014, 11, 30.	1.1	16
39	Hormone receptor expression patterns in the endometrium of asymptomatic morbidly obese women before and after bariatric surgery. <i>Gynecologic Oncology</i> , 2014, 133, 78-82.	0.6	32
40	Genetic Risk Assessment for Women with Epithelial Ovarian Cancer: Referral Patterns and Outcomes in a University Gynecologic Oncology Clinic. <i>Journal of Genetic Counseling</i> , 2013, 22, 662-673.	0.9	34
41	Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. <i>Cytotherapy</i> , 2013, 15, 1297-1306.	0.3	54
42	A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. <i>Gynecologic Oncology</i> , 2013, 128, 65-70.	0.6	89
43	Development and pilot of an advance care planning website for women with ovarian cancer: A randomized controlled trial. <i>Gynecologic Oncology</i> , 2013, 131, 430-436.	0.6	43
44	Patient Satisfaction with Physician Discussions of Treatment Impact on Fertility, Menopause and Sexual Health among Pre-menopausal Women with Cancer. <i>Journal of Cancer</i> , 2012, 3, 217-225.	1.2	78
45	A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. <i>Cytotherapy</i> , 2011, 13, 98-107.	0.3	374
46	Use of allogeneic NK cells for cancer immunotherapy. <i>Immunotherapy</i> , 2011, 3, 1445-1459.	1.0	134
47	A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2011, 121, 112-117.	0.6	64
48	Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1877-1884.	2.0	61
49	A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the "sandwich" method for high risk endometrial carcinoma. <i>Gynecologic Oncology</i> , 2010, 118, 19-23.	0.6	43
50	Learning about ovarian cancer at the time of diagnosis: Video versus usual care. <i>Gynecologic Oncology</i> , 2010, 119, 370-375.	0.6	15
51	Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients. <i>Journal of Ovarian Research</i> , 2010, 3, 21.	1.3	94
52	Chemotherapy Induces Macrophage Chemoattractant Protein-1 Production in Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 918-925.	1.2	42
53	The Use of Sodium Hyaluronate-Carboxymethylcellulose (HA-CMC) Barrier in Gynecologic Malignancies: A Retrospective Review of Outcomes. <i>Annals of Surgical Oncology</i> , 2009, 16, 499-505.	0.7	13
54	Feasibility and morbidity of using saline filled tissue expanders to reduce radiation-induced bowel injury in patients with gynecologic malignancies. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2009, 143, 93-97.	0.5	7

#	ARTICLE	IF	CITATIONS
55	Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression. <i>Gynecologic Oncology</i> , 2004, 95, 632-636.	0.6	47